Using a specially designed capsule, researchers can now voyage through the digestive system, collecting new data about digestion and microorganisms. The work by a team including researchers at the University of California, Davis, Stanford University and Envivo Bio Inc., is published May 10 in papers in Nature and Nature Metabolism.
Most of the process of digestion takes place in our small intestine, where enzymes break down food so it can be absorbed through the gut wall.
“The small intestine has so far only been accessible in sedated people who have fasted, and that’s not very helpful,” said Professor Oliver Fiehn, director of the West Coast Metabolomics Center at UC Davis. Metabolomics is the study of the metabolome, the small molecules involved in metabolism in cells, tissues and organs. Fiehn is senior author on the Nature Metabolism paper and co-corresponding author on the Nature paper. Jacob Folz, a postdoctoral researcher at UC Davis, is first author on the Nature Metabolism paper.
As a result, most studies of gut metabolism and the gut microbiome are based on stool samples, but stool samples are really sampling the lower colon, not the small intestine.
“Measuring gut metabolites in stool is like studying an elephant by examining its tail,” said Dari Shalon of Envivo Bio, inventor of the CapScan device and co-author on the papers. “Most metabolites are made, transformed and utilized higher up in the intestines and don’t even make it into the stool. CapScan gives us a fuller picture of the gut metabolome and its interactions with the gut microbiome for the first time.”
The capsule is swallowed and collects a small volume of biofluids and microorganisms on the way from the upper intestine to the colon until it is recovered in stool. By using a pH-sensitive coating on the capsule, the researchers could choose which area of the intestinal tract to sample.
“This capsule and reports are the first of their kind,” Fiehn said. “All other studies on human gut microbiota focused on stool as a surrogate for colon metabolism. However, of course, the fact is that 90% of human digestion happens in the upper intestine, not the colon.”
First study of normal digestion
The researchers were able to look at the variation in upper intestinal contents during normal daily digestion in 15 healthy people.
They used a ‘multiomics’ approach to analyze the samples for bacteria, viruses, host proteins and metabolites from food. They found that the upper intestine and stool differed in all these areas, sometimes dramatically, and identified nearly 2,000 metabolites. The team also found associations between diet, including fruit and alcohol, and metabolites.
Two individuals who had taken antibiotics in the previous six months showed large variations in levels of bioactive fatty acid esters of hydroxy fatty acids (FAFHAs) and sulfonolipids, metabolites that are thought to be associated with preventing inflammation and diabetes. A species of bacteria named Blautia was identified as most involved in fatty acid metabolism.
“Overall, this device can help elucidate the roles of the gut microbiome and metabolome in human physiology and disease,” Fiehn said.
Additional authors on the Nature Metabolism paper are: Juan Montes Morales, UC Davis; Rebecca Neal Culver, Jessica Grembi, David Relman, and Kerwyn Casey Huang, Stanford University School of Medicine; and George Triadafilopoulos, Silicon Valley Neurogastroenterology and Motility Center. Except for Montes Morales, they are also authors on the Nature paper, along with: Peter Treit, Florian Rosenberger, Philipp Geyer, Johannes Mueller-Reif and Matthias Mann, Max-Planck Institute of Biochemistry, Martinsried, Germany; Handuo Shi, Les Dethlefsen, Eitan Yaffe, Andrés Aranda-Díaz, Sean Spencer and Susan Holmes, Stanford University; Xiandong Meng, Chan Zuckerberg Biohub, San Francisco; and Andrew Patterson, Pennsylvania State University.
The work was supported in part by the National Science Foundation, the National Institutes of Health and the Bill and Melinda Gates Foundation.
Method of Research
Subject of Research
Profiling the human intestinal environment under physiological conditions
Article Publication Date
Dari Shalon is an employee of Envivo Bio, Inc. (San Francisco, CA) and owns stock in the company. Shalon is an inventor on pending patent application WO2018213729 covering the sampling device described in the manuscript, which is owned by Envivo Bio, Inc. All other authors declare no competing interests.